FDA approves Lynparza for the maintenance treatment of germline BRCA-mutated metastatic pancreatic adenocarcinoma AstraZeneca + Merck Inc.
The approval follows the recommendation from the US FDA Oncologic Drugs Advisory Committee (ODAC) on 17 December for Lynparza in this indication, and was based on results from the pivotal Phase III POLO trial published in The New England Journal of Medicine and presented at the 2019 American Society of Clinical Oncology Annual Meeting.
Results showed a statistically significant and clinically meaningful improvement in progression-free survival, where Lynparza nearly doubled the time patients with gBRCAm metastatic pancreatic cancer lived without disease progression or death to a median of 7.4 months vs. 3.8 months on placebo. The safety and tolerability profile of Lynparza in the POLO trial was in line with that observed in prior clinical trials.
Related news and insights
CTI BioPharma Corp. announced the FDA has extended the review period for the New Drug Application (NDA) for pacritinib for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis (MF) with a baseline platelet count of <50 × 109 l.
ImmunoGen announced positive top-line data from the pivotal SORAYA trial evaluating the safety and efficacy of IMGN 853 (mirvetuximab soravtansine monotherapy in patients with folate receptor alpha (FR?)-high platinum-resistant ovarian cancer who have been previously treated with Avastin (bevacizumab).